Phase 2 N=406 Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Breast Cancer · Carcinoma of the Breast
Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=189 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
Phase 2 N=60 Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Breast Cancer
Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants
N/A N=49 Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Breast Cancer Metastases · HER2 Positive Breast
Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants
Phase 2 N=51 Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early…
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Phase 2 N=31 Cardiac Safety Study in Patients With HER2 + Breast Cancer
HER2 Positive Breast Cancer · Left Ventricular Function Systolic Dysfunction
Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants
Phase 2 N=100 Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Breast Cancer
Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants
Phase 3 N=736 A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 8.0; 8.7; 8.8 Months — p=0.0318
Phase 2 N=32 Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Breast Cancer
Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants
Phase 2 N=140 HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
N/A N=580 An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
Phase 2 N=275 Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Breast Cancer
Primary: Disease-free Survival (DFS) — 89.8; 83.8 Percentage of participants who survived — p=0.18
N/A N=283 Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Part II: Objective Response Rate of HER2-negative Metastatic Breast Cancer (by FISH Testing) — 7 percentage of participants
Phase 2 N=72 Phase II Trial for Large ER-Negative Breast Cancers
Malignant Neoplasm of Female Breast
Primary: Overall Response Rate — 25; 21 Participants
Phase 2 N=32 Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Breast Cancer
Primary: Pathologic Complete Response — 26 percentage of participants
Phase 2 N=78 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) of MTD/Phase II Patients — 4.0 months
Phase 2 N=24 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
Breast Cancer
Primary: Change in Ki-67 in Breast Tissue of High-Risk Women
Phase 2 N=25 Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
HER2 Positive Breast Carcinoma · Stage IV Breast Cancer AJCC v6 and v7
Primary: Percent of Participants With Grade 2 or Higher Toxicities — 80 percentage of participants
Phase 4 N=44 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
First or Second Line HER2-negative Breast Cancer · Metastatic Disease Without Bone Metastasis
Primary: Number of Participants With Progression Free Survival (PFS) — 9; 19; 6; 10 Participants
Phase 3 N=652 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Phase 2 N=72 A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response (pCR) — 24.2 percentage of participants
Phase 2 N=81 Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
Breast Cancer
Primary: Pathological Complete Response After Preoperative Therapy With Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in Patients With HER-2 Positive Early Breast…
Phase 2 N=21 Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Phase 2 N=30 Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
Breast Neoplasm
Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants
Phase 2 N=95 Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Breast Cancer
Primary: Number of Patients Who Completed All Planned Therapy — 45 participants
Phase 2 N=136 Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Breast Neoplasms · Neoplasms
Primary: 16-week Progression Free Survival — 58.2; 77.8 percentage of participants
Phase 2 N=50 An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
Breast Neoplasms
Primary: Objective Response (OR) — 0 Participants with OR
N/A N=111 A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Clinical Benefit — 53; 20; 5; 7 Participants